Coherus Oncology (CHRS) Projected to Post Earnings on Monday

Coherus Oncology (NASDAQ:CHRS) is expected to issue its Q4 2025 results after the market closes on Monday, March 9th. Analysts expect Coherus Oncology to post earnings of ($0.31) per share and revenue of $14.0930 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Monday, March 9, 2026 at 4:30 PM ET.

Coherus Oncology Price Performance

Shares of NASDAQ CHRS opened at $1.82 on Friday. The stock’s 50-day simple moving average is $1.77 and its two-hundred day simple moving average is $1.54. Coherus Oncology has a twelve month low of $0.71 and a twelve month high of $2.62. The firm has a market capitalization of $272.04 million, a P/E ratio of 1.37 and a beta of 1.04. The company has a quick ratio of 1.23, a current ratio of 1.24 and a debt-to-equity ratio of 0.42.

Wall Street Analysts Forecast Growth

CHRS has been the topic of several research analyst reports. Wall Street Zen upgraded shares of Coherus Oncology from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Oppenheimer initiated coverage on shares of Coherus Oncology in a research report on Thursday, January 22nd. They set an “outperform” rating and a $10.00 target price for the company. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $5.51.

Institutional Trading of Coherus Oncology

Large investors have recently modified their holdings of the business. Jefferies Financial Group Inc. raised its position in Coherus Oncology by 2.5% during the 3rd quarter. Jefferies Financial Group Inc. now owns 325,625 shares of the biotechnology company’s stock valued at $534,000 after purchasing an additional 8,000 shares during the last quarter. Corient Private Wealth LLC increased its stake in shares of Coherus Oncology by 20.0% during the second quarter. Corient Private Wealth LLC now owns 60,000 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 10,000 shares during the period. BNP Paribas Financial Markets increased its stake in shares of Coherus Oncology by 108.2% during the third quarter. BNP Paribas Financial Markets now owns 26,620 shares of the biotechnology company’s stock valued at $44,000 after buying an additional 13,832 shares during the period. Quarry LP bought a new position in shares of Coherus Oncology during the third quarter valued at approximately $26,000. Finally, Ieq Capital LLC raised its holdings in shares of Coherus Oncology by 24.9% during the fourth quarter. Ieq Capital LLC now owns 79,128 shares of the biotechnology company’s stock valued at $112,000 after acquiring an additional 15,751 shares in the last quarter. 72.82% of the stock is owned by institutional investors.

Coherus Oncology Company Profile

Coherus Oncology, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacturing and commercialization of biologic therapies for oncology support and immuno-oncology. Founded in 2010 and headquartered in Redwood City, California, Coherus specializes in biosimilar versions of established oncology agents as well as novel immunotherapy candidates.

The company’s lead marketed products include Udenyca (pegfilgrastim-cbqv) and Fulphila (pegfilgrastim-jmdb), biosimilars to Amgen’s Neulasta, which are designed to reduce the incidence of infection in patients undergoing myelosuppressive chemotherapy.